IRulya Therapeutics Inc. SEC filings IRLA
IRulya Therapeutics Inc. has 462 filings in SEC EDGAR's recent list, going back to Jan 5, 2016. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 24, 2026 | — |
| D | Filing | Jun 11, 2026 | — |
| D | Filing | Jun 11, 2026 | — |
| NT 10-K | Filing | Apr 1, 2026 | Dec 31, 2025 |
| EFFECT | Filing | Aug 5, 2025 | — |
| CORRESP | Letter to the SEC | Aug 1, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 1, 2025 | — |
| D | Filing | Jul 1, 2025 | — |
| EFFECT | Filing | Dec 26, 2024 | — |
| CORRESP | Letter to the SEC | Dec 23, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 23, 2024 | — |
| 8-A12B | Filing | Apr 5, 2023 | — |
| EFFECT | Filing | May 17, 2022 | — |
| POS EX | Filing | May 17, 2022 | — |
| POSASR | Filing | Feb 7, 2022 | — |
| EFFECT | Filing | Apr 13, 2020 | — |
| CORRESP | Letter to the SEC | Apr 9, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2020 | — |
| EFFECT | Filing | May 8, 2019 | — |
| CORRESP | Letter to the SEC | May 6, 2019 | — |
| CORRESP | Letter to the SEC | May 6, 2019 | — |
| CERT | Filing | May 6, 2019 | — |
| 8-A12B | Filing | May 1, 2019 | — |
| CORRESP | Letter to the SEC | Apr 29, 2019 | — |
| CORRESP | Letter to the SEC | Apr 29, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2019 | — |
| CORRESP | Letter to the SEC | Apr 12, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 2, 2019 | — |
| DRS | Filing | Mar 4, 2019 | — |
| D | Filing | May 31, 2018 | — |
| D | Filing | Feb 14, 2017 | — |
| D | Filing | Jan 5, 2016 | — |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IRLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1662774
- Former names
- Quince Therapeutics, Inc. (until Oct 9, 2026); Cortexyme, Inc. (until Aug 1, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.